Baudax Bio, Inc. (BXRXQ)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Oct 25, 2024, 8:30 AM EST
Baudax Bio Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '23 Sep 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2017 |
| Revenue | 1.27 | 1.27 | 1.08 | 0.49 | - | - | Upgrade
|
| Revenue Growth (YoY) | 217.25% | 17.50% | 119.07% | - | - | - | Upgrade
|
| Cost of Revenue | 7.01 | 7.01 | 2.45 | 1.73 | - | - | Upgrade
|
| Gross Profit | -5.74 | -5.74 | -1.37 | -1.24 | - | - | Upgrade
|
| Selling, General & Admin | 19 | 24.12 | 45.31 | 43.34 | 22.61 | 29.45 | Upgrade
|
| Research & Development | 8.29 | 3.89 | 3.13 | 9.09 | 17.26 | 35.58 | Upgrade
|
| Operating Expenses | 29.28 | 30 | 51.01 | 54.57 | 39.87 | 65.04 | Upgrade
|
| Operating Income | -35.02 | -35.74 | -52.38 | -55.81 | -39.87 | -65.04 | Upgrade
|
| Interest Expense | - | - | - | -1.36 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -2.68 | -1.98 | -2.31 | -16.69 | -0.04 | -0.13 | Upgrade
|
| EBT Excluding Unusual Items | -37.71 | -37.72 | -54.68 | -73.86 | -39.91 | -65.17 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | -7.2 | - | Upgrade
|
| Asset Writedown | -23.84 | -23.84 | - | - | - | - | Upgrade
|
| Other Unusual Items | 2.8 | 2.76 | 34.91 | -2.25 | 14.55 | -8.5 | Upgrade
|
| Pretax Income | -58.75 | -58.8 | -19.77 | -76.1 | -32.56 | -73.67 | Upgrade
|
| Net Income | -7.15 | -58.8 | -19.77 | -76.1 | -32.56 | -73.67 | Upgrade
|
| Net Income to Common | -7.61 | -58.8 | -19.77 | -76.1 | -32.56 | -73.67 | Upgrade
|
| Shares Outstanding (Basic) | 4 | 0 | 0 | 0 | - | - | Upgrade
|
| Shares Outstanding (Diluted) | 4 | 0 | 0 | 0 | - | - | Upgrade
|
| Shares Change (YoY) | 2403.74% | 505.82% | 311.07% | - | - | - | Upgrade
|
| EPS (Basic) | -1.91 | -177.30 | -361.16 | -5714.93 | - | - | Upgrade
|
| EPS (Diluted) | -1.91 | -177.30 | -361.16 | -5714.93 | - | - | Upgrade
|
| Free Cash Flow | -14.35 | -27.81 | -49.47 | -44.7 | -51.36 | -63.12 | Upgrade
|
| Free Cash Flow Per Share | -3.60 | -83.87 | -903.81 | -3356.64 | - | - | Upgrade
|
| Gross Margin | - | - | -126.39% | -251.32% | - | - | Upgrade
|
| Operating Margin | -2759.89% | -2816.63% | -4849.63% | -11319.88% | - | - | Upgrade
|
| Profit Margin | -599.61% | -4633.18% | -1830.46% | -15436.11% | - | - | Upgrade
|
| Free Cash Flow Margin | -1130.58% | -2191.73% | -4580.83% | -9066.33% | - | - | Upgrade
|
| EBITDA | -34.76 | -35.58 | -52.14 | -55.4 | -39.39 | -64.64 | Upgrade
|
| D&A For EBITDA | 0.26 | 0.17 | 0.24 | 0.41 | 0.48 | 0.4 | Upgrade
|
| EBIT | -35.02 | -35.74 | -52.38 | -55.81 | -39.87 | -65.04 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.